<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chaudhuri, Padmaparna</style></author><author><style face="normal" font="default" size="100%">Paraskar, Abhimanyu</style></author><author><style face="normal" font="default" size="100%">Soni, Shivani</style></author><author><style face="normal" font="default" size="100%">Mashelkar, Raghunath Anant</style></author><author><style face="normal" font="default" size="100%">Sengupta, Shiladitya</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Fullerenol-cytotoxic conjugates for cancer chemotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">ACS Nano</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">doxorubicin</style></keyword><keyword><style  face="normal" font="default" size="100%">drug delivery</style></keyword><keyword><style  face="normal" font="default" size="100%">fullerenol</style></keyword><keyword><style  face="normal" font="default" size="100%">nanoparticle</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">SEP</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">9</style></number><publisher><style face="normal" font="default" size="100%">AMER CHEMICAL SOC</style></publisher><pub-location><style face="normal" font="default" size="100%">1155 16TH ST, NW, WASHINGTON, DC 20036 USA</style></pub-location><volume><style face="normal" font="default" size="100%">3</style></volume><pages><style face="normal" font="default" size="100%">2505-2514</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;In the present study, we report the novel application of polyhydroxylated fullerenes (fullerenols) in cancer drug delivery. The facile synthetic procedure for generating multiple hydroxyl groups on the fullerene cage offers scope for high drug loading in addition to conferring hydrophilicity. Doxorubicin, a first line cancer chemotherapeutic, was conjugated to fullerenols through a carbamate linker, achieving ultrahigh loading efficiency. The drug-fullerenol conjugate was found to be relatively stable in phosphate buffer saline but temporally released the active drug when incubated with tumor cell lysate. The fullerenol-doxorubicin conjugate suppressed the proliferation of cancer cell-lines in vitro through a G2-M cell cycle block, resulting in apoptosis. Furthermore, in an in vivo murine tumor model, fullerenol-doxorubicin exhibited Comparable antitumor efficacy as free drug without the systemic toxicity of free doxorubicin. Additionally, we demonstrate that the fullerenol platform can be extended to other chemotherapeutic agents, such as the slightly water-soluble cisplatin, and can emerge as a new paradigm in the management of cancer.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">9</style></issue><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">9.855</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kundu, Tanay</style></author><author><style face="normal" font="default" size="100%">Mitra, Shouvik</style></author><author><style face="normal" font="default" size="100%">Patra, Prasun</style></author><author><style face="normal" font="default" size="100%">Goswami, Arunava</style></author><author><style face="normal" font="default" size="100%">Diaz, David Diaz</style></author><author><style face="normal" font="default" size="100%">Banerjee, Rahul</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mechanical downsizing of a gadolinium(iii)-based metal-organic framework for anticancer drug delivery</style></title><secondary-title><style face="normal" font="default" size="100%">Chemistry-A European Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">ball-milling</style></keyword><keyword><style  face="normal" font="default" size="100%">doxorubicin</style></keyword><keyword><style  face="normal" font="default" size="100%">drug delivery</style></keyword><keyword><style  face="normal" font="default" size="100%">metal-organic frameworks</style></keyword><keyword><style  face="normal" font="default" size="100%">nanocarriers</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">AUG</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">33</style></number><publisher><style face="normal" font="default" size="100%">WILEY-V C H VERLAG GMBH</style></publisher><pub-location><style face="normal" font="default" size="100%">BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY</style></pub-location><volume><style face="normal" font="default" size="100%">20</style></volume><pages><style face="normal" font="default" size="100%">10514-10518</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;A Gd-III-based porous metal-organic framework (MOF), Gd-pDBI, has been synthesized using fluorescent linker pDBI (pDBI=(1,4-bis(5-carboxy-1H-benzimidazole-2-yl)benzene)), resulting in a three-dimensional interpenetrated structure with a one-dimensional open channel (1.9x1.2nm) filled with hydrogen-bonded water assemblies. Gd-pDBI exhibits high thermal stability, porosity, excellent water stability, along with organic-solvent and mild acid and base stability with retention of crystallinity. Gd-pDBI was transformed to the nanoscale regime (ca. 140nm) by mechanical grinding to yield MG-Gd-pDBI with excellent water dispersibility (&amp;gt;90min), maintaining its porosity and crystallinity. In vitro and in vivo studies on MG-Gd-pDBI revealed its low blood toxicity and highest drug loading (12wt%) of anticancer drug doxorubicin in MOFs reported to date with pH-responsive cancer-cell-specific drug release.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">33</style></issue><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">6.35
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chekin, Fereshteh</style></author><author><style face="normal" font="default" size="100%">Myshin, Vladyslav</style></author><author><style face="normal" font="default" size="100%">Ye, Ran</style></author><author><style face="normal" font="default" size="100%">Melinte, Sorin</style></author><author><style face="normal" font="default" size="100%">Singh, Santosh K.</style></author><author><style face="normal" font="default" size="100%">Kurungot, Sreekumar</style></author><author><style face="normal" font="default" size="100%">Boukherroub, Rabah</style></author><author><style face="normal" font="default" size="100%">Szunerits, Sabine</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Graphene-modified electrodes for sensing doxorubicin hydrochloride in human plasma</style></title><secondary-title><style face="normal" font="default" size="100%">Analytical and Bioanalytical Chemistry</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Disposable electrodes</style></keyword><keyword><style  face="normal" font="default" size="100%">doxorubicin</style></keyword><keyword><style  face="normal" font="default" size="100%">Nitrogen-doped reduced graphene oxide</style></keyword><keyword><style  face="normal" font="default" size="100%">Serum</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">MAR</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">411</style></volume><pages><style face="normal" font="default" size="100%">1509-1516</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Doxorubicin (DOX), an anthracycline molecule, is currently one of the most widely used anticancer drugs in clinics. Systematic treatment of patients with DOX is known to be accompanied by several unpleasant side effects due to the toxicity of the drug. Thus, monitoring of DOX concentration in serum samples has become increasingly important to avoid side effects and ensure therapeutic efficiency. In this study, we discuss the construction of a disposable electrochemical sensor for the direct monitoring of DOX in clinical blood samples. The sensor is based on coating a gold electrode in a flexible integrated electrode construct formed on polyimide sheets using photolithography, with nitrogen-doped reduced graphene oxide (N-rGO) suspended in chitosan. Under optimized conditions, a linear relationship between the oxidative peak current and the concentration of DOX in the range of 0.010-15M with a detection limit of 10nM could be achieved. The sensor was adapted to monitor DOX in serum samples of patients under anticancer treatment.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;3.286&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kulkarni-Dwivedi, Neha</style></author><author><style face="normal" font="default" size="100%">Patel, Pratikshkumar R.</style></author><author><style face="normal" font="default" size="100%">Shravage, V. Bhupendra</style></author><author><style face="normal" font="default" size="100%">Umrani, Rinku D.</style></author><author><style face="normal" font="default" size="100%">Paknikar, Kishore M.</style></author><author><style face="normal" font="default" size="100%">Jadhav, Sachin H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hyperthermia and doxorubicin release by Fol-LSMO nanoparticles induce apoptosis and autophagy in breast cancer cells</style></title><secondary-title><style face="normal" font="default" size="100%">Nanomedicine</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Autophagy</style></keyword><keyword><style  face="normal" font="default" size="100%">Breast cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">combination therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">doxorubicin</style></keyword><keyword><style  face="normal" font="default" size="100%">Folic acid</style></keyword><keyword><style  face="normal" font="default" size="100%">hyperthermia</style></keyword><keyword><style  face="normal" font="default" size="100%">LSMO</style></keyword><keyword><style  face="normal" font="default" size="100%">MDA-MB231 cells</style></keyword><keyword><style  face="normal" font="default" size="100%">PEG</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">OCT</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">1929-1949</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	Background: Studies on the anticancer effects of lanthanum strontium manganese oxide (LSMO) nanoparticles (NPs)-mediated hyperthermia at cellular and molecular levels are scarce. Materials &amp;amp; methods: LSMO NPs conjugated with folic acid (Fol-LSMO NPs) were synthesized, followed by doxorubicin-loading (DoxFol-LSMO NPs), and their effects on breast cancer cells were investigated. Results: Hyperthermia (45 degrees C) and combination treatments exhibited the highest (similar to 95%) anticancer activity with increased oxidative stress. The involvement of intrinsic mitochondria-mediated apoptotic pathway and induction of autophagy was noted. Cellular and molecular evidence confirmed the crosstalk between apoptosis and autophagy, involving Beclin1, Bcl2 and Caspase-3 genes with free reactive oxygen species presence. Conclusion: The study confirmed hyperthermia and doxorubicin release by Fol-LSMO NPs induces apoptosis and autophagy in breast cancer cells.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">25</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	6.096&lt;/p&gt;
</style></custom4></record></records></xml>